Baseline and follow-up data from contacts B and D
| Time point | Outcomes measured |
| Contact B | Further demographic information including date of birth and date of diagnosis of PD |
| Full screening questions according to inclusion and exclusion criteria | |
| Medication regime and calculation of Levodopa equivalent daily dose | |
| H&Y score | |
| MoCA | |
| BDI II, AS, ESS | |
| Timed Up and Go Test | |
| NMSS | |
| PDSS-2 | |
| RBD-SQ | |
| Contact D (the SPHERE house stay) | MDS-UPDRS (the motor subscale will be performed on multiple occasions, once while ‘off’ medications) |
| PDQ-39 | |
| Symptom and activity diary | |
| Sleep diary | |
| Bladder diary | |
| Medication-taking record | |
| Sensor data from scripted activities | |
| Sensor data from free-living | |
| Sensor data from wearable devices provided through IXICO | |
| Annotations of colour video dataset | |
| Gait mat assessments | |
| Interview with questions relating to experience of living with SPHERE technology |
AS, Apathy Scale; BDI BDI II, Beck’s Depression Inventory II; ESS, Epworth Sleepiness Scale; H&Y, Hoehn and Yahr; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptoms Scale for Parkinson’s disease; PD, Parkinson's disease; PDQ-39, Parkinson’s Disease Questionnaire-39; PDSS-2, Parkinson’s Disease Sleep Scale-2; RBD-SQ, REM sleep Behaviour Disorder Screening Questionnaire; SPHERE, Sensor Platform for HEalthcare in a Residential Environment.